Valuation of a radiolabeled peptide for diagnosis of pulmonary diseases

Challenge: In preparation for fundraising, a biotech company developing a clinical stage radiolabeled peptide to diagnose pulmonary diseases required an independent valuation of its technology in...
Learn More

Valuation of Rx and OTC products for an investor

Challenge: An investor and asset manager was considering an investment in a European biotech company with one development product for hemophilia and another approved OTC product in an unrelated...
Learn More

Valuation of an integrin-targeting oncology asset

Challenge A preclinical-stage company developing an integrin-targeting oncology asset engaged Alacrita to quantify the value potential of its lead asset in pancreatic ductal adenocarcinoma (PDAC),...
Learn More

Valuation of deal for prophylactic mAbs against SARS-CoV-2

Challenge A recently emerged biotech company developing prophylactic monoclonal antibodies (mAbs) against a major viral target for immunocompromised patients asked Alacrita to develop an independent...
Learn More

Global sales forecast for a small molecule in hepatocellular carcinoma

Challenge A UK-based oncology drug development company was planning to in license a small molecule in development for hepatocellular carcinoma (HCC) and Rhabdomyosarcoma. Alacrita was commissioned to...
Learn More

Valuation of novel formulation of insulin for diabetes

Challenge A preclinical stage biotech company developing a novel formulation of insulin to treat diabetes mellitus was in discussions with prospective investors for a next round of funding. To...
Learn More

Valuation of a portfolio of therapeutics for an investment firm

Challenge An investment firm required independent valuations of five therapeutics within two of its portfolio companies, including four preclinical programs and a proprietary formulation of a...
Learn More

Valuation of a small molecule therapeutic for enhanced male infertility

Challenge A biotech company had developed preclinical data supporting the use of its lead drug candidate in enhancing male fertility. The product was being considered for both ex-vivo usage prior to...
Learn More

Oncology clinical expert input and asset valuation

Challenge A clinical stage immuno-oncology biotech company spun out from a leading university had completed a Phase I clinical trial in ovarian cancer patients with its lead antibody. In response to...
Learn More

Preclinical & clinical asset pipeline valuation

Challenge: A young biotech company with a portfolio of clinical and pre-clinical stage bispecific antibodies (BsAb) to treat various cancers was in the process of completing a Series A funding round....
Learn More

Valuation of a repurposed, male-fertility drug using Monte Carlo

Challenge: A client developing a repurposed drug for use in male fertility asked Alacrita to conduct a valuation for the asset in the US and EU4+UK in support of impending deal negotiations. The...
Learn More

Valuation of a biotech company using Monte Carlo

Challenge: A biotechnology startup had entered a major licensing deal with Big Pharma and was able to fund operations via the upfront payment rather than needing to raise a Series A. This introduced...
Learn More
1 2 3 4